Please ensure Javascript is enabled for purposes of website accessibility

Novavax net loss up, revenue down

Novavax Inc., of Gaithersburg, a clinical-stage vaccine company, reported its net loss more than doubled and revenue dropped $2 million for the quarter ended Dec. 31. Novavax posted a net loss of $31.5 million, or 13 cents per share, compared with $14.1 million and 7 cents for the same period in 2013. Revenue in 2014’s quarter was $6.7 million, down from $8.7 million. For the year, Novavax finished with a net loss of $82.9 million, or 37 cents per share, compared with $52.0 million and 31 cents in 2013. “We have initiated five clinical trials within the last six months, including advancing both our RSV and seasonal influenza programs into Phase 2 clinical trials, while introducing our new Ebola vaccine into the clinic,” Stanley C. Erck, president and chief executive officer, said in a statement. “These achievements underscore the strength of our vaccine technology, capability of our manufacturing platform and experience of our leadership team.”